Gold vs US Dollar

Register for streaming realtime charts, analysis tools, and prices.

Get Started

Home
Investing
Stocks
UK
LSE
Croda International Plc (CRDA) Share Price

CRDA Croda International Plc

4,649.00

-5.00 (-0.11%)

25 Apr 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Croda International Plc	LSE:CRDA	London	Ordinary Share	GB00BJFFLV09	ORD 10.609756P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-5.00	-0.11%	4,649.00	619,672	16:35:00

Bid Price		Offer Price	High Price	Low Price	Open Price
4,643.00		4,647.00	4,775.00	4,561.00	4,678.00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Chemicals & Chem Preps, Nec	1.69B	171M	1.2246	37.94	6.49B

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
17:16:49	O	79	4,610.19	GBX

Related Shares
Johnson Matthey (JMAT), Synthomer (SYNT), Hardide (HDD), Byotrol (BYOT)

Croda (CRDA) Latest News (3)

Croda News

Date	Time	Source	Headline
25/4/2024	10:01	UK RNS	Croda International PLC Result of AGM
24/4/2024	07:00	UK RNS	Croda International PLC First quarter 2024 sales update
11/4/2024	14:11	UK RNS	Croda International PLC Director/PDMR Shareholding
08/4/2024	10:54	UK RNS	Croda International PLC Director/PDMR Shareholding
08/4/2024	10:23	UK RNS	Croda International PLC Director/PDMR Shareholding
28/3/2024	09:17	UK RNS	Croda International PLC Director/PDMR Shareholding
26/3/2024	16:19	UK RNS	Croda International PLC Director/PDMR Shareholding
26/3/2024	16:10	UK RNS	Croda International PLC Director/PDMR Shareholding
26/3/2024	16:09	UK RNS	Croda International PLC Director/PDMR Shareholding
26/3/2024	16:09	UK RNS	Croda International PLC Director/PDMR Shareholding

More Croda News

Croda Investors Croda Takeover Rumours

Croda (CRDA) Discussions and Chat

Croda Forums and Chat

Date	Time	Title	Posts
24/4/2024	20:48	CRODA	317
24/7/2018	22:20	Croda Intl (CRDA) One to Watch on Wednesday	-
23/7/2014	15:31	TipTv analyses the prospects of Croda International PLC (CRDA)	-
25/7/2012	20:28	CRODA BACK TO Ј7	253
05/2/2007	14:35	Strong Outlook	98

Add a New Thread

Croda (CRDA) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
16:17:03	4,610.19	79	3,642.05	O
16:17:03	4,584.72	16	733.55	O
16:15:33	4,641.79	89	4,131.19	O
16:14:08	4,610.02	112	5,163.22	O
16:13:49	4,656.10	249	11,593.70	O

View all Croda trades in real-time

Croda (CRDA) Top Chat Posts

Top Posts
Posted at 25/4/2024 09:20 by Croda Daily Update Croda International Plc is listed in the Chemicals & Chem Preps, Nec sector of the London Stock Exchange with ticker CRDA. The last closing price for Croda was 4,654p. Croda currently has 139,635,400 shares in issue. The market capitalisation of Croda is £6,395,301,320. Croda has a price to earnings ratio (PE ratio) of 37.40. This morning CRDA shares opened at 4,678p Read Full Thread Reply
Posted at 27/2/2024 07:49 by battyliveson Poor numbers, but probably expected given share price movements in last couple of years. I think a fair value for croda is around £4.4 to £5.6bn, so will wait before I get back in. B Read Full Thread Reply
Posted at 05/2/2024 16:38 by wad collector Bouncing off £50 atm , maybe the worse is behind CRDA now, this is an industry with high barriers to entry , but still a long way back to the heady £100 days of 2021. Read Full Thread Reply
Posted at 14/12/2023 14:02 by smcni1968 Croda a long C-road to recoveryOperationally, a load C-road to recovery. We reduce Croda estimates c. 12% for FY24 and our target price to £53. In Consumer Care, we expect a sequential improvement in destocking; however, as demonstrated above, the overhang of inventories at HPC customers remains into the start of FY24. With a realignment of customer inventories globally still ongoing (esp. in Asia) and slower growth from large-cap customers more generally, the snap-back will not be immediate. This has raised and continues to raise debate around the defensiveness and quality of Croda's Consumer Care portfolio, given volume declines well in excess of even its lowest-quality peers, despite the cushioning from substantial growth in Iberchem.From an earnings perspective, even with stabilising volumes y/y, earnings remain impacted by operating deleverage and high-priced inventories. With it clear Ag end markets are unlikely to recover until H2. While volumes seem to be turning (Actives up y/y, Beauty Effects still negative) and despite work on inventories, we are not completely out of the woods, with inventories still above average. Risk therefore remains that the boost in volumes through September/October is short-lived near term, and thus, the outlook remains weak. We expect a weak 1H24 - essentially reflecting the 2H run rates, with a more meaningful improvement coming through as the year progresses.Strategically, poised but not yet able to catalyse growth given operational challenges. In the mid-term, Croda's less levered balance sheet than peers provides optionality from an acquisition perspective, with ND/EBITDA still c1x (at current EBITDA levels c1.4x). In the near term, the ability to acquire businesses remains constrained, with the attractive IFF Lucas Meyer assets too expensive, given current uncertainties in outlook and in managing the core business. Overall, that high-multiple stocks can get these deals executed at these multiples is another affirmation that multiples in the sector remain too high. For Croda to participate further in acquisitions, we believe a meaningful decline in industry multiples must be evident in asset prices. Read Full Thread Reply
Posted at 19/9/2023 16:27 by commuter10 This gives real cause for concern as share price has now halved from Mid-2021 levels. Is this a hold or sell share now do we think? Read Full Thread Reply
Posted at 19/6/2023 17:34 by steeplejack And another one… JPMorgan Cazenove slashed its price target on Croda to 5,000p from 6,200p and retained its 'underweight' rating. The bank said the new price target is based on around 22x 2025 estimate price-to-earnings, with the target multiple still reflecting an optimistic premium to last 10years. JPM said the company's recent earnings reset by management reduces near-term risks, although the visibility on 2H23/2024 earnings recovery remains low, in the bank's opinion. "Further, fundamentally, a pronounced earnings decline in 2023 with an implied 5-year organic EBIT compound annual growth rate of circa 2% and around 8-9% points decline in post-tax ROIC over this period (due to a step-up in M&A and to a lesser extent organic growth capex) do not justify the market expectations of a structural substantial step-up in organic growth and as a result substantial re-rating of the shares seen over the past four years, in our opinion," it said. JPM's lowered FY23/24 adjusted earnings per share estimates are 5%/11% below post-warning company consensus. "Some of the current earnings pressure - 2023E adjusted EBIT likely to be down 15% year-on-year ex Covid-19 vaccines related earnings - reflect the sector-wide cyclical downturn and inventory destocking trends," it said. "However, the company has likely also continued to lose material market share in its consumer care business, in which 2023e volumes are likely to be around 15% below 2018 levels." Read Full Thread Reply
Posted at 15/6/2023 21:55 by steeplejack Berenberg cut its price target on Croda as it trimmed estimates a week after the specialty chemicals firm warned on profits, but maintained its 'buy' recommendation. The bank, which reduced the price target to £66 from £80 ,said big profit warnings from Croda are rare - as are good entry points. “The last time the company issued a trading update remotely as bearish as the one of 9 June 2023 was on 24 June 2014, when industrials were a larger part of mix," it noted. “The smooth journey for Croda over the difficult subsequent period for the chemicals sector - one of Chinese overcapacity, then the Covid-19 pandemic, then the European energy crisis - speaks for the robustness of the business. "The recovery of shares,following the 2014 warning, suggests it is a good idea to buy on weakness. We understand that US order books show some signs of improvement, and survey data (see our consumer team's China review) point to a solid outlook for China. "Europe is not yet at the end of squeeze on discretionary incomes, but volumes should improve by the start of FY24." Berenberg said the 20% cuts to its earnings per share estimates reflect lower sales volumes and prices in consumer care and crop protection, in addition to lower prices for by-product sales in the industrial specialities segment. Read Full Thread Reply
Posted at 07/6/2023 08:19 by steeplejack Goldman Sachs cuts Croda International to 'neutral' (buy) - price target 7,200 (8,700) pence Read Full Thread Reply
Posted at 06/4/2023 17:48 by wad collector Somebody paid 65.50 for 200k shares this afternoon, woke the price up a bit. Those heady days of £100 back in 2021 look a long way away still though. Read Full Thread Reply
Posted at 01/3/2023 08:16 by steeplejack The Directors are recommending a final dividend of 61.0p per share amounting to a total of GBP85.1m in respect of the financial year ended 31 December 2022. Subject to shareholder approval, the dividend will be paid on 26 May 2023 to shareholders registered on 28 April 2023. The total proposed dividend for the year ended 31 December 2022 will be 108.0p per share amounting to GBP150.7m. Read Full Thread Reply
Posted at 23/12/2021 15:48 by philanderer Croda: Vaccine boost offsets industrial sale There was some disappointment at the decision of chemicals specialist Croda (CRDA) to sell its bio-based industrial business, but the stock remains well ahead this year thanks to its vaccine exposure, according to Hargreaves Lansdown. The group reported the sale of its bio-based industrial business to US firm Cargill Velocity for £778m following a review of this part of the business. The price tag has, however, disappointed some investors, as the shares eased 0.4% to £99.42. Analyst Susannah Streeter said it was still one of the FTSE 100’s best performers in 2021, up 48% over the year thanks to strong first-half results and full-year profits forecast to beat earlier expectations. ‘The extent to which Croda is benefiting from the ongoing vaccine boom has become clear over recent months and it’s down to its investment in innovative technologies,’ she said. ‘It supplies lipid nanoparticles for Pfizer’s mRNA technology and given the demand for booster jabs, that area of life sciences is bounding along.’ Streeter said even when vaccine demand wanes there will still be demand for ‘a broader range of use of its products in medical treatments like oncology’. ‘Recovery in consumer markets has also helped its personal care sector which focuses on ingredients for skin, hair, and cosmetic products and the focus on sustainability should help drive sales among an increasingly eco-conscious customer base,’ said Streeter. citywire.com Read Full Thread Reply

Croda share price data is direct from the London Stock Exchange

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions